Centrix Pharmaceutical, Inc. announces Agreement with CutisPharma, Inc. to promote FIRST® - Progesterone VGS compounding kit
BIRMINGHAM, Ala. – Centrix Pharmaceutical, Inc., a privately-held specialty pharmaceutical company focused on Pediatrics and Women’s Health, announces a promotional agreement with CutisPharma, Inc., a Woburn, Massachusetts based company. The partnership will include the promotion of FIRST® - Progesterone VGS, vaginal suppository compounding kits.
Beginning early July, 2011, Centrix Pharmaceutical sales representatives will promote FIRST®- Progesterone VGS compounding kits from CutisPharma, Inc. in physician offices, clinics, and hospitals who specialize in obstetrics and gynecology in addition to retail pharmacies nationwide.
About FIRST® - Progesterone VGS compounding kit
The product line includes FIRST® - Progesterone VGS 25, 50, 100, 200, and 400. The kits are made for one patient and include pre-weighed progesterone, and suppository base, and a unique, patented disposable suppository mold for preparation, dispensing, and storage of the suppositories, all in one unit that increases patient compliance, and ease of use.
FIRST® - Progesterone VGS saves dispensing time, and can be compounded by the pharmacist while the patient waits, increasing customer satisfaction. Using FIRST® VGS kits, the pharmacist can compound a prescription for 30 vaginal suppositories 4 to 5 times faster than those prepared in the conventional way using a metal suppository mold or polystyrene shells. A single NDC number assigned for the entire kit facilitates the third party reimbursement process, and reduces audit-related adjustments.
About Centrix Pharmaceutical, Inc.
Centrix Pharmaceutical is a privately-held specialty pharmaceutical company focused in Pediatrics and Women’s Health. Headquartered in Birmingham, AL, the Company’s products are marketed by its dedicated sales force in the United States. For more information about Centrix Pharmaceutical, Inc. visit www.cenrx.com.
About CutisPharma, Inc.
CutisPharma, Inc. based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on the development and commercialization of value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 10 million currently compounded prescriptions, by offering FIRST® Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Three U.S. patents have been issued to the Company with several additional patents pending. For more information about Cutis Pharma, Inc., visit www.cutispharma.com.
Centrix Pharmaceutical, Inc. announces Copromote Agreement with Norgenix Pharmaceuticals LLC, to promote Paire OB™ Plus DHA and Maxaron® Forte
February 1, 2011 – BIRMINGHAM, Ala. – Centrix Pharmaceutical, Inc., a privately-held specialty pharmaceutical company focused on Pediatrics and Women's Health, announces a copromote agreement with Norgenix Pharmaceuticals, LLC, a Spartanburg, South Carolina based company. The partnership will include the co-promotion of Paire OB™ Plus DHA, a prenatal/postnatal vitamin/mineral supplement, and Maxaron® Forte, an iron supplement for iron deficiency anemia.
Beginning February 1, 2011, Norgenix sales representatives will promote Paire OB™ Plus DHA and Maxaron® Forte along with Centrix Pharmaceutical sales representatives in physician offices, clinics, and hospitals who specialize in obstetrics and gynecology.
About Paire OB™ Plus DHA Paire OB™ Plus DHA is a prenatal/postnatal multivitamin/mineral tablet and a softgel capsule containing an Omega-3 fatty acid nutritional supplement indicated for use in improving the nutritional status of women throughout pregnancy and in the postnatal period for both lactating and non-lactating mothers. Paire OB™ Plus DHA is also beneficial in improving the nutritional status of women prior to conception.
About Maxaron® Forte
Maxaron® Forte capsules are indicated for the prevention and treatment of iron deficiency anemia and/or nutritional megaloblastic anemias.
About Centrix Pharmaceutical, Inc.
Centrix Pharmaceutical is a privately-held specialty pharmaceutical company focused in Pediatrics and Women’s Health. Headquartered in Birmingham, AL, the Company's products are marketed by its dedicated sales force in the United States. For more information about Centrix Pharmaceutical, Inc. visit www.cenrx.com.
About Norgenix Pharmaceuticals, LLC
Norgenix, a wholly owned subsidiary of the JM Smith Corporation, is a North American specialty pharmaceutical, medical device, and biotech company that engages in the development, commercialization and sales of pharmaceutical products in the women’s health market. Founded in 2008, Norgenix offers quality products that provide solutions to the unmet needs within women's health. With products spanning the continuum of care from pharmaceutical therapies to medical devices, Norgenix is licensed to sell, market, and distribute prescription drug products and medical devices in the United States. www.norgenixpharma.com
Important Safety Information
Paire OB™ Plus DHA and Maxaron® Forte contain iron. Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. These products have a black box warning because of potential iron therapy overload. Acute iron poisoning is rare in adults but can be fatal in children under 6 who take adult-strength tablets. Some patients on iron therapy may experience constipation, diarrhea, and abdominal pain, but these symptoms are usually transient. They are rarely severe, although iron tablets can aggravate existing astrointestinal problems. Some people have reported allergic reactions to folic acid. Black stools are common when taking iron tablets. Maxaron® Forte should not be used for people who suffer from hemochromatosis or hemosiderosis.
For full prescribing information please visit www.cenrx.com
For Additional Information Contact:
Centrix Pharmaceutical, Inc.
1-866-991-9870 info@cenrx.com www.cenrx.com
Paire OB™ Plus DHA is a prenatal/postnatal multivitamin/mineral tablet and a softgel capsule containing an Omega-3 fatty acid nutritional supplement indicated for use in improving the nutritional status of women throughout pregnancy and in the postnatal period for both lactating and non-lactating mothers. Paire OB™ Plus DHA is also beneficial in improving the nutritional status of women prior to conception.
About Maxaron® Forte
